{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'f Prior to any screening assessments: all patient >6 years of age (or above an age determined by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) and in according with the local regulations', 'and requirements) and their parent(s)/caregiver(s)/legal guardian(s) will receive information about the study, on study objective(s) and procedures, to the fullest extent possible, in their language and in terms they', 'are able to understand, and must sign and date the IRB/IEC approved Informed Assent Form (IAF) and Informed Consent Form (ICF), respectively. For girls who have started menstruating, a specific assent form', 'must be obtained.', 'g Medical history, asthma-specific medical history (ie, family history of atopy & Ig E mediated disease [particularly maternal], premature birth and/or, low birthweight, exposure to tobacco smoke, recurring viral', 'infections in early childhood), surgical history.', 'h Reversibility of at least 10% in FEV1 after the administration of 200 to 400 mcg (2 to 4 puff inhalations with metered-dose inhaler [MDI]) of albuterol/salbutamol or 45 to 90 mcg (2 to 4 puffs with MDI) of', 'levalbuterol/levosalbutamol reliever medication before randomization (up to 3 opportunities during the same visit are allowed with a maximum of 12 puffs of reliever medication if tolerated by the patient).', 'Documented reversibility or positive airway hyper-responsiveness to methacholine within 12 months prior to Screening V1 is considered acceptable. If the subject does not meet this reversibility criterion at', 'Screening V1, up to 2 additional assessment attempts can be performed at any time between Screening and Baseline Visit 2.', 'i', 'A separate assent must be obtained from female patients at the earliest visit when the investigator is notified that the first menses', 'have', 'occurred.', 'j', 'Vital signs, including blood pressure (mmHg), heart rate (beats per minute), respiratory rate (breaths per minute), body temperature (degrees Celsius), height (cm) and body weight (kg) will be measured at the', 'Screening and Randomization visits (Visits 1 and 2) and every subsequent visit. Vital signs will be measured in the sitting position using the same arm at each visit, and will be measured prior to receiving', 'investigational product at the clinic visits.', 'k Electronic diary/PEF meter is used for daily recording of salbutamol/albuterol or levosalbutamol/levalbuterol use, asthma controller drug use, oral steroid requirements, nocturnal awakenings due to asthma', 'symptoms requiring the use of reliever medications, morning and evening asthma symptom NRS scores and AM and PM PEF. This device is dispensed at Visit 1 and information is downloaded from this device on', 'the other indicated days.', '/', 'During the Randomized Treatment Period IMP administrations, every 2 week (q2w), will be performed by the Investigator at scheduled study site visits (must be separated by at least 11 days) up to Week 50. In', 'the first 12 weeks (up to V8), patients will be monitored at the study site for a minimum of 30 minutes after injection of IMP, to assess any injection reactions (see Section 8.1.4 for more details). After', \"randomization, dose regimen will not be adjusted for patient's age or weight until the randomized treatment will be completed.\", 'm Home Dosing and training of parent(s)/caregive((s)/legal guardian(s): For all visits scheduled only for IMP administration (ie, at Weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50), parent(s)/caregiver(s))/legal', 'guardian(s) may decide to do the injection of IMP at home (ie, home administration of IMP). These parent(s)/caregiver(s)/legal guardian(s) will be trained by the Investigator or designee to administer IMP, by', 'demonstration at V2, V3, and V4 (injections performed by Investigator). After parent(s)/caregiver(s)/legal guardian(s) have successfully administered IMP under close supervision of the Investigator at V5-V8', '(Weeks 6, 8, 10, and 12), the Investigator may approve them to perform home administration of IMP at all further visits that do not require a scheduled visit. It is possible to start home administration at any visit', 'following V9, provided parent(s)/caregiver(s)/legal guardian(s) have been trained by the investigator or designee to administer IMP by demonstration at not less than 3 visits followed by a successful IMP', 'administration under close supervision of the investigator or designee at not less than 3 visits.', 'However, if parent(s)/caregiver(s)/legal guardian(s) do not develop the comfort to inject the IMP at home, or the Investigator determines that injection by parent(s)/caregiver(s))legal guardian(s) at home is not', \"appropriate, alternative arrangements may be made: for example for qualified site personnel and/or healthcare professionals (eg, visiting nurse service) to administer IMP at these timepoints at the patient's home.\", 'n Forced expiratory volume (FEV1), PEF, forced vital capacity (FVC), forced expiratory flow between 25% to 75% of vital capacity (FEF25%-75%) at all visits; pulmonary function tests should be performed in the', 'morning if possible, but if it could only be done at a different time of the day, the spirometry should be done at approximately the same time of the day at each visit throughout the study. Spirometry will be', 'performed after a wash out period of bronchodilators according to their action duration, for example, withholding the last dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours, withholding', 'the last dose of LABA for at least 12 hours, and withholding the last dose of LAMA for at least 24 hours. This will be verified before performing the PEF measurements.', 'o', 'Treatment Period stability limits will be established for FEV1 and PEF. Period stability limit for PEF is defined as the respective mean AM or PM PEF obtained over the last 7 days prior to Visit 2 (Day1). There', \"should be at least 4 days' measurement for setting up the stability limit, and the first dosing visit should be rescheduled until data for 4 days are available.\", 'p Asthma Control Questionnaire-Interviewer Administered (ACQ-IA, for children 6 to <12 years), ACQ-7 and ACQ-5 scores and Paediatric Asthma Quality of Life Questionnaire With Standardised Activities-', 'Interviewer Administered (PAQLQ(S)-IA) score, for children >7 years old at Randomization V2, are administered by the interviewer during the study visits at the clinical site. The ACQ-7 score will be used to follow', 'up evaluations in all patients. The ACQ-5 (the first 5 items of the ACQ-7) score is used for eligibility evaluation at Screening V1 and Baseline V2 for all patients.', 'q', 'Pediatric rhinoconjunctivitis quality of life questionnaire-Interviewer Administered (PRQLQ-IA): For those patients with comorbid allergic rhinitis, administered by the interviewer during the study visits at the clinical', 'site.', 'r', 'Biomarker set includes serum Thymus and Activation-Regulated Chemokine (TARC).', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 24']\n\n###\n\n", "completion": "END"}